UNSPSC 51393704: Pelrinone hydrochloride

This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H11N5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51K948JB05, chemically known as 1,4-dihydro-2-methyl-4-oxo-6-((3-pyridylmethyl)amino)-5-pyrimidinecarbonitrile monohydrochloride but more generally known as pelrinone hydrochloride, which bears US NIH Compound Identifier 55919. Most nations, for tariff and trade purposes, schedule pelrinone hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, PELRINONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pelrinone hydrochloride bears US NLM identifiers UMLS ID C2983940 and NCI Concept Code C90920. SMILES: CC1[NH]C(C(C(=O)N1)C#N)NCC2CCCNC2.CL.

UNSPSC 51393704 Pelrinone hydrochloride is a Commodity code that in state and local procurement activity covers pharmaceutical products and related medical supplies procured for community health and emergency response initiatives. The recent opportunity under this code reflects state and local governments' acquisition of naloxone and drug deactivation systems to support public health programs, particularly opioid response and harm-reduction efforts. Issuing bodies soliciting under this code include county health departments and public safety agencies managing community health initiatives.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The contract requires quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping costs. The initial two-year term includes an optional one-year renewal, and the procurement is potentially funded through FEMA with associated federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. Vendors must maintain workers' compensation, commercial general liability, and professional liability insurance; comply with drug-free workplace certification and E-Verify requirements; and are subject to a three-month probationary period allowing termination with or without cause. The geographic focus for recent activity is Florida, specifically the Central Florida region.